Lactobacillus crispatus HGG35 for preventing and / or treating premature delivery and application thereof

Abstract

The invention provides lactobacillus crispatus HGG35 for preventing and / or treating premature delivery and application of the lactobacillus crispatus HGG35, and belongs to the technical field of microorganisms. The lactobacillus crispatus HGG35 is preserved in the China Center for Type Culture Collection, the address is Wuhan University, Wuhan, China, the preservation date is November 30, 2023, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: M 20232399. The lactobacillus crispatus HGG35 disclosed by the invention can produce hydrogen peroxide, L-lactic acid and D-lactic acid at high yield, has an obvious inhibition effect on common harmful strains in vagina, and can improve the balance of vaginal flora. The lactobacillus crispatus HGG35 disclosed by the invention has remarkable effects of preventing and treating premature delivery, and can be used for remarkably prolonging the pregnancy period, preventing premature delivery of fetuses and ensuring normal development of the fetuses.

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms, and in particular to a Lactobacillus crispatus HGG35 for preventing and / or treating premature birth and an application thereof. Background Art

[0002] Identifying high-risk factors and providing preventive measures can reduce the risk of spontaneous preterm birth. A previous second-trimester spontaneous abortion or delivery is the strongest risk factor for spontaneous preterm birth. Although the incidence of second-trimester abortion or delivery is estimated to be approximately 1% of deliveries, pregnancy after spontaneous preterm birth remains a clinical challenge. The risk of recurrence in women with a history of preterm birth ranges from 15% to more than 50% and is inversely proportional to the number of weeks of gestation at which the previous preterm birth occurred. In addition, 70% of women with this risk factor typically deliver within 2 days. The gestational age at which the first birth occurs is at or near the limit of viability, which is associated with high neonatal mortality and morbidity. History is often provided to indicate cervical cerclage or progesterone, but the cause of recurrent preterm birth is not known. In fact, a history of spontaneous preterm birth often has multiple potential causes, and despite appropriate research, no obvious cause is found in up to half of patients. It is critical to distinguish the causes and implement preventive measures that target the causes.

[0003] Bacterial infection that ascends from the vagina into the uterine cavity is thought to be the primary cause of approximately half of spontaneous preterm birth cases; the earlier the spontaneous preterm birth occurs, the more likely it is to be caused by infection. The risk of infection is high during the second trimester. However, current guidelines for spontaneous preterm birth do not include screening and prevention strategies targeting the vaginal microbiota.

[0004] Low sensitivity and the inability to detect microbiota composition by culture-based methods may be the main reason why a clear relationship between infection and spontaneous preterm birth has not been elucidated so far. In 2014, 16S rRNA sequencing was first used to evaluate the relationship between bacteria and spontaneous preterm birth. To date, although some studies have been conducted, inconsistent conclusions have been reached. Currently, there are no measures to prevent and control preterm birth that target the microbial composition of the vaginal and uterine cavities. Summary of the invention

[0005] The purpose of the present invention is to provide a Lactobacillus crispatus HGG35 for preventing and / or treating premature birth and its application. The Lactobacillus crispatus HGG35 of the present invention can produce high levels of hydrogen peroxide, L-lactic acid, and D-lactic acid, has a significant inhibitory effect on common harmful bacteria in the vagina, and can improve the balance of vaginal flora. The Lactobacillus crispatus HGG35 of the present invention has a significant effect of preventing and treating premature birth, can significantly prolong the pregnancy period, prevent premature birth of the fetus, and ensure the normal development of the fetus.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides a strain of Lactobacillus crispatus HGG35, wherein the Lactobacillus crispatus HGG35 is deposited in China Center for Type Culture Collection, address: Wuhan University, Wuhan, China, the deposit date is: November 30, 2023, and the deposit number is CCTCCNO: M20232399.

[0008] Preferably, the 16S rDNA sequence of the Lactobacillus crispatus HGG35 is shown as SEQ ID NO.1.

[0009] The present invention also provides a composition for preventing and / or treating premature birth, wherein the composition comprises the Lactobacillus crispatus HGG35.

[0010] Preferably, the concentration of Lactobacillus crispatus HGG35 in the composition is 10 7 ~10 9 CFU / mL.

[0011] The present invention also provides a use of the Lactobacillus crispatus HGG35 or the composition in preparing a medicine for preventing and / or treating premature birth.

[0012] Preferably, the method of using the drug is vaginal transplantation.

[0013] The present invention provides a Lactobacillus crispatus HGG35 for preventing and / or treating premature birth and its application. The Lactobacillus crispatus HGG35 of the present invention is separated from the human body and has reliable safety. The Lactobacillus crispatus HGG35 of the present invention has the ability to produce high levels of hydrogen peroxide and lactic acid, and hydrogen peroxide and lactic acid can inhibit the number of harmful bacteria in the human vagina, maintain the normal balance of human vaginal flora, and reduce infectious diseases. Animal experiments have shown that compared with other Lactobacillus crispatus and chemical drugs, the strain of the present invention can significantly prolong the pregnancy period, prevent and treat premature birth, improve the development of the fetus in the mother's body, and reduce children's diseases caused by premature birth.

[0014] Collection Instructions

[0015] Lactobacillus crispatus HGG35, the strain is deposited in China Center for Type Culture Collection, address: Wuhan University, Wuhan, China. The deposit date is November 30, 2023, and the deposit number is CCTCCNO: M20232399. DETAILED DESCRIPTION

[0016] The present invention provides a strain of Lactobacillus crispatus HGG35, wherein the Lactobacillus crispatus HGG35 is deposited in China Center for Type Culture Collection, address: Wuhan University, Wuhan, China, the deposit date is: November 30, 2023, and the deposit number is CCTCCNO: M20232399.

[0017] In the present invention, the 16S rDNA sequence of the Lactobacillus crispatus HGG35 is shown as SEQ ID NO.1.

[0018] The present invention also provides a composition for preventing and / or treating premature birth, wherein the composition comprises the Lactobacillus crispatus HGG35.

[0019] In the present invention, the concentration of Lactobacillus crispatus HGG35 in the composition is preferably 10 7 ~10 9 CFU / mL, more preferably 10 8 CFU / mL.

[0020] The present invention also provides a use of the Lactobacillus crispatus HGG35 or the composition in preparing a medicine for preventing and / or treating premature birth.

[0021] In the present invention, the method of using the drug is preferably vaginal transplantation.

[0022] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0023] Example 1

[0024] This example provides a strain of Lactobacillus crispatus HGG35, which is isolated from vaginal secretions of healthy women of childbearing age. The strain is inoculated on MRS solid medium and cultured at 37°C to obtain round colonies with rough surfaces. Under a microscope, the strain is a Gram-positive bacterium in the shape of short rods.

[0025] Among them, the formula of MRS solid culture medium is: 10g / L peptone, 5g / L yeast extract, 10g / L beef extract, 20g / L glucose, 5g / L sodium acetate, 2g / L sodium citrate, 1mL / L Tween-80, 0.58g / L MgSO4·7H2O, 0.25g / LMgSO4·4H2O, 2g / LK2HPO4, 20g / L agar powder, pH 6.4, 121℃ high pressure steam sterilization.

[0026] According to the method in the literature (Establishment of a 16S rDNA sequencing method for rapid identification of contaminating bacteria in blood products, Ying Yanling et al., Chinese Journal of Microbiology and Immunology, Issue 10, 2009), the 16S rDNA sequence of the strain of the present invention was sequenced, and the sequencing result is shown in SEQ ID NO.1.

[0027] SEQ ID NO.1 is as follows:

[0028] GCCTTAGACGGCTCCTTCCCGAAGGTTAGGCCACCGGCTTTGGGCATTGC

[0029] AGACTCCCATGGTGTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATT

[0030] CACCGCGGCGTGCTGATCCGCGATTACTAGCGATTCCAGCTTCGTGCAGT

[0031] CGAGTTGCAGACTGCAGTCCGAACTGAGAACAGCTTTCAGAGATTCGCT

[0032] TGCCTTCGCAGGCTCGCTTCTCGTTGTACTGCCCATTGTAGCACGTGTGTA

[0033] GCCCAGGTCATAAGGGGCATGATGACTTGACGTCATCCCCACCTTCCTCC

[0034] GGTTTGTCACCGGCAGTCTCATTAGAGTGCCCAACTTAATGCTGGCAACT

[0035] AATAACAAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACA

[0036] CGAGCTGACGACAGCCATGCACCACCTGTCTTAGCGTCCCCGAAGGGAA

[0037] CTTTGTATCTCTACAAATGGCACTAGATGTCAAGACCTGGTAAGGTTCTTC

[0038] GCGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCGT

[0039] CAATTCCTTTGAGTTTCAACCTTGCGGTCGTACTCCCCAGGCGGAGTGCT

[0040] TAATGCGTTAGCTGCAGCACTGAGAGGCGGAAACCTCCCAACACTTAGC

[0041] ACTCATCGTTTACGGCATGGACTACCAGGGTATCTAATCCTGTTCGCTACC

[0042] CATGCTTTCGAGCCTCAGCGTCAGTTGCAGACCAGAGAGCCGCCTTCGC

[0043] CACTGGTGTTCTTCCATATATCTACGCATTCCACCGCTACACATGGAGTTC

[0044] CACTCTCCTCTTCTGCACTCAAGAAAAACAGTTTCCGATGCAGTTCCTCG

[0045] GTTAAGCCGAGGGCTTTCACATCAGACTTATTCTTCCGCCTGCGCTCGCTT

[0046] TACGCCCAATAAATCCGGACAACGCTTGCCACCTACGTATTACCGCGGCT

[0047] GCTGGCACGTAGTTAGCCGTGACTTTCTGGTTGATTACCGTCAAATAAAG

[0048] GCCAGTTACTACCTCTATCCTTCTTCACCAACAACAGAGCTTTACGATCCG

[0049] AAAACCTTCTTCACTCACGCGGCGTTGCTCCATCAGACTTGCGTCCATTG

[0050] TGGAAGATTCCCTACTGCTGCCTCCCGTAGGAGTTTGGGCCGTGTCTCAG

[0051] TCCCAATGTGGCCGATCAGTCTCTCAACTCGGCTATGCATCATCGCCTTGG

[0052] TAAGCCTTTACCTTACCAACTAGCTAATGCACCGCGGGGCCATCCCATAGC

[0053] GACAGCTTACCGCCGCCTTTTAAAAGCTGATCATGCGATCTGCTTTCTTATC

[0054] CGGTATTAGCACCTGTTTCCAAGTGGTATCCCAGACTATGGGGCAGGTTC

[0055] CCCACGTGTTACTCACCCATCCGCCGCTCGCTTTCCTAACGTCATTGCCGA

[0056] AGTAAATCTGTTAGTTCCGCTCGCTCGACTTGCATGTATTAGGCACGCCGC

[0057] CAGCGTTCGT

[0058] The BLAST comparison analysis of the GenBank database confirmed that the strain of the present invention belongs to Lactobacillus crispatus and is named Lactobacillus crispatus HGG35. The strain was sent to the China Center for Type Culture Collection for preservation on November 30, 2023, with a preservation number of CCTCCNO: M20232399.

[0059] Example 2

[0060] This example detects the content of metabolites (hydrogen peroxide and sodium lactate) in the bacterial liquid of Lactobacillus crispatus HGG35, and the specific process is as follows:

[0061] (1) Hydrogen peroxide content

[0062] Lactobacillus crispatus HGG35 was inoculated into MRS liquid culture medium at an inoculation rate of 2%, and cultured at 37° C. for 24 hours to obtain a bacterial liquid of Lactobacillus crispatus HGG35.

[0063] Among them, the formula of MRS liquid culture medium is: 10g / L peptone, 5g / L yeast extract, 10g / L beef extract, 20g / L glucose, 5g / L sodium acetate, 2g / L sodium citrate, 1mL / L Tween-80, 0.58g / L MgSO4·7H2O, 0.25g / LMgSO4·4H2O, 2g / LK2HPO4, pH6.4, 121℃ high pressure steam sterilization.

[0064] 1 mL of bacterial solution was centrifuged, and the supernatant was taken. A hydrogen peroxide content detection kit (purchased from Beijing Solaibao Technology Co., Ltd.) was used to detect the hydrogen peroxide content in the bacterial solution according to the instructions. Lactobacillus crispatus CGMCC 6363 and Lactobacillus crispatus ATCC 202225 were used as controls. The ability of Lactobacillus crispatus CGMCC 6363 and Lactobacillus crispatus ATCC202225 to produce hydrogen peroxide was detected according to the above method. The test results are shown in Table 1.

[0065] Table 1 Hydrogen peroxide content of bacterial suspensions of various strains

[0066] Bacteria Hydrogen peroxide concentration (μmoL / mL) Lactobacillus crispatus HGG35 6.82 Lactobacillus crispatus CGMCC6363 5.94 Lactobacillus crispatus ATCC202225 6.37

[0067] (2) Lactic acid content

[0068] Lactobacillus crispatus HGG35 was inoculated in MRS liquid medium with an inoculum size of 2%, and cultured at 37°C for 24h to obtain Lactobacillus crispatus HGG35 bacterial liquid. 1mL bacterial liquid was centrifuged, and the supernatant was taken. D-lactic acid (D-LA) content detection kit and L-lactic acid (L-LA) content detection kit (purchased from Beijing Solebow Technology Co., Ltd.) were used to detect the content of L-lactic acid and D-lactic acid in the bacterial liquid according to the instructions. With Lactobacillus crispatus CGMCC 6363 and Lactobacillus crispatus ATCC 202225 as controls, the ability of Lactobacillus crispatus CGMCC 6363 and Lactobacillus crispatus ATCC 202225 to produce lactic acid was detected according to the above method. The test results are shown in Table 2.

[0069] Table 2 Lactic acid content of bacterial suspension of each strain

[0070] Bacteria L-Lactic acid concentration (g / L) D-lactic acid concentration (g / L) Lactobacillus crispatus HGG35 9.43 15.11 Lactobacillus crispatus CGMCC6363 8.26 12.57 Lactobacillus crispatus ATCC202225 6.37 8.66

[0071] It can be seen from Tables 1 and 2 that the Lactobacillus crispatus HGG35 of the present invention has significant ability to produce hydrogen peroxide and lactic acid.

[0072] Example 3

[0073] This example uses an in vitro antibacterial experiment to detect the inhibitory effect of Lactobacillus crispatus HGG35 on common harmful bacteria in the human body. The specific process is as follows:

[0074] Test bacteria: Candida albicans, Salmonella, Staphylococcus aureus and Gardnerella.

[0075] Test strains: Lactobacillus crispatus HGG35, Lactobacillus crispatus CGMCC 6363 culture liquid and Lactobacillus crispatus ATCC202225.

[0076] Test method: Activate the test bacteria and use sterile water to make a concentration of 1×10 610mL sterile PDA culture medium (45 ℃) is mixed with 100 μ L bacterial liquid, poured into sterile culture dish, and left to solidify. The lactobacillus crispatus HGG35 bacterial liquid, lactobacillus crispatus CGMCC 6363 bacterial liquid and lactobacillus crispatus ATCC 202225 bacterial liquid obtained by embodiment 2 cultivation are centrifuged, and supernatant is taken, and the sterile filter paper with a diameter of 5mm is immersed in the supernatant of above-mentioned different strains respectively, and takes out after soaking 5min, and the filter paper is placed on the culture dish with the addition of test strain, and each test strain is all set to 3 repetitions. After 24h, the inhibition zone diameter is detected and averaged. The result is as shown in Table 3.

[0077] Table 3 Diameter of inhibition zone of each bacterial strain against different test strains (mm)

[0078]

[0079] As can be seen from Table 3, the Lactobacillus crispatus HGG35 of the present invention has a significant inhibitory effect on common vaginal harmful bacteria such as Candida albicans, Salmonella, Staphylococcus aureus and Gardnerella, indicating that the Lactobacillus crispatus HGG35 of the present invention can improve the balance of vaginal flora and reduce bacterial infection diseases.

[0080] Example 4

[0081] This embodiment provides the use of Lactobacillus crispatus HGG35 in preventing premature birth. The specific process is as follows:

[0082] (1) Lactobacillus crispatus HGG35 was inoculated into MRS liquid medium and cultured at 37°C until the bacterial liquid concentration reached 10 8 CFU / mL, and obtain the bacterial liquid of Lactobacillus crispatus HGG35.

[0083] (2) Twenty 8-week-old female C57 mice weighing 15.0 g ± 2 g were randomly divided into an experimental group and a control group. Male C57 mice of the same age were selected and housed with the mice in an independent cage at a 1:1 ratio. Vaginal plugs were detected to determine whether pregnancy occurred. The detection of the plug was considered to be the 0.5 day of pregnancy.

[0084] (3) The experimental group received Lactobacillus crispatus HGG35 bacterial liquid transplantation on the third day of pregnancy, that is, 150 μl of bacterial liquid was injected into the vagina. The control group received 150 μl of PBS injected into the vagina on the third day of pregnancy.

[0085] (4) On gestational day 15.5, all pregnant mice were injected with LPS (25 μg / kg diluted in 100 μl, serotype 055:B5, Sigma, USA) into the amniotic cavity.

[0086] The delivery date of the experimental group and the control group was monitored, and the average delivery date was calculated. The results are shown in Table 4.

[0087] Table 4 Average delivery day of pregnant mice in each group

[0088] Group Experimental Group Control group delivery day Gestational age 19.7 ± 1.5 days* Gestational age 17.3 ± 1.8 days

[0089] Note: * indicates p<0.05

[0090] As can be seen from Table 4, transplanting Lactobacillus crispatus HGG35 bacterial liquid into the vagina of pregnant mice can significantly prolong the pregnancy time and prevent premature birth.

[0091] Example 5

[0092] This embodiment provides the application of Lactobacillus crispatus HGG35 in treating premature birth. The specific process is as follows:

[0093] (1) Lactobacillus crispatus HGG35 was inoculated into MRS liquid medium and cultured at 37°C until the bacterial liquid concentration reached 10 8 CFU / mL, and obtain the bacterial liquid of Lactobacillus crispatus HGG35.

[0094] (2) Twenty 8-week-old female C57 mice weighing 15.0 g ± 2 g were randomly divided into an experimental group and a control group. Male C57 mice of the same age were selected and housed with the mice in an independent cage at a 1:1 ratio. Vaginal plugs were detected to determine whether pregnancy occurred. The detection of the plug was considered to be the 0.5 day of pregnancy.

[0095] (3) On gestational day 15.5, all pregnant mice were injected with LPS (25 μg / kg diluted in 100 μl, serotype 055:B5, Sigma, USA) into the amniotic cavity.

[0096] (4) After LPS injection, the experimental group immediately underwent Lactobacillus crispatus HGG35 bacterial liquid transplantation, i.e., 150 μl of bacterial liquid was injected into the vagina; the control group immediately underwent 150 μl of PBS injection into the vagina.

[0097] The delivery date of the experimental group and the control group was monitored, and the average delivery date was calculated. The results are shown in Table 5.

[0098] Table 5 Average delivery day of pregnant mice in each group

[0099] Group Experimental Group Control group delivery day Gestation 18.4 ± 1.4 days* 17.1±1.6 days of gestation

[0100] Note: * indicates p<0.05

[0101] As can be seen from Table 5, transplanting Lactobacillus crispatus HGG35 bacterial liquid into the vagina of pregnant mice can treat premature birth caused by external factors and significantly prolong the pregnancy time.

[0102] Example 6

[0103] This example tests the preventive or therapeutic effects of different species of Lactobacillus crispatus on premature birth, and the specific process is as follows:

[0104] (1) Lactobacillus crispatus HGG35 was inoculated into MRS liquid medium and cultured at 37°C until the bacterial liquid concentration reached 10 8 CFU / mL, and obtain the bacterial liquid of Lactobacillus crispatus HGG35.

[0105] Lactobacillus crispatus CGMCC 6363 was inoculated into MRS liquid medium and cultured at 37°C until the bacterial concentration reached 10 8 CFU / mL, and the bacterial liquid of Lactobacillus crispatus CGMCC 6363 was obtained.

[0106] Lactobacillus crispatus ATCC202225 was inoculated into MRS liquid medium and cultured at 37°C until the bacterial concentration reached 10 8 CFU / mL, and obtained the bacterial liquid of Lactobacillus crispatus ATCC202225.

[0107] (2) Thirty 8-week-old female C57 mice weighing 15.0 g ± 2 g were randomly divided into the experimental group, control group 1, and control group 2. Male C57 mice of the same age were selected and housed with the mice in an independent cage at a 1:1 ratio. Vaginal plugs were detected to determine whether pregnancy occurred. The detection of the plug was considered to be the 0.5 day of pregnancy.

[0108] (3) The experimental group received Lactobacillus crispatus HGG35 bacterial liquid transplantation on the third day of pregnancy, i.e., 150 μl of bacterial liquid was injected into the vagina; the control group 1 received Lactobacillus crispatus CGMCC6363 bacterial liquid injection using the same method, and the control group 2 received Lactobacillus crispatus ATCC202225 bacterial liquid injection using the same method.

[0109] (4) On gestational day 15.5, all pregnant mice were injected with LPS (25 μg / kg diluted in 100 μl, serotype 055:B5, Sigma, USA) into the amniotic cavity.

[0110] The delivery date of the experimental group and each control group was monitored, and the average delivery date was calculated. The results are shown in Table 6.

[0111] Table 6 Average delivery day of pregnant mice in each group

[0112] Group Experimental Group Control group 1 Control group 2 delivery day Pregnancy 19.8±1.5d 18.4±1.7 days of gestation 18.6±1.2 days of gestation

[0113] As can be seen from Table 6, different types of Lactobacillus crispatus have different effects on the prevention or treatment of premature birth, and the Lactobacillus crispatus HGG35 of the present invention has the best effect on prolonging pregnancy time.

[0114] Example 7

[0115] This example tests the preventive or therapeutic effects of Lactobacillus crispatus HGG35 and chemical drugs on premature birth. The specific process is as follows:

[0116] (1) Lactobacillus crispatus HGG35 was inoculated into MRS liquid medium and cultured at 37°C until the bacterial liquid concentration reached 10 8 CFU / mL, and obtain the bacterial liquid of Lactobacillus crispatus HGG35.

[0117] (2) Twenty 8-week-old female C57 mice weighing 15.0 g ± 2 g were randomly divided into an experimental group and a control group. Male C57 mice of the same age were selected and housed with the mice in an independent cage at a 1:1 ratio. Vaginal plugs were detected to determine whether pregnancy occurred. The detection of the plug was considered to be the 0.5 day of pregnancy.

[0118] (3) The experimental group received Lactobacillus crispatus HGG35 bacterial liquid transplantation on the third day of pregnancy, i.e., 150 μl of bacterial liquid was injected into the vagina; the control group received an injection of 150 μl of progesterone (diluted to a concentration of 0.8 μg / μL with PBS).

[0119] (4) On gestational day 15.5, all pregnant mice were injected with LPS (25 μg / kg diluted in 100 μl, serotype 055:B5, Sigma, USA) into the amniotic cavity.

[0120] The delivery date of the experimental group and each control group was monitored, and the average delivery date was calculated. The results are shown in Table 7.

[0121] Table 7 Average delivery day of pregnant mice in each group

[0122] Group Experimental Group Control group delivery day Gestation 20.1 ± 1.8 days* Pregnancy 18.9±1.2d

[0123] Note: * indicates p<0.05

[0124] It can be seen from Table 7 that the Lactobacillus crispatus HGG35 bacterial liquid of the present invention has a better prevention or treatment effect on premature birth than the chemical drug progesterone.

[0125] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A strain of Lactobacillus crispatus HGG35, characterized in that: The Lactobacillus crispatus HGG35 is deposited in the China Center for Type Culture Collection, address: Wuhan University, Wuhan, China. The deposit date is: November 30, 2023, and the deposit number is CCTCCNO: M20232399.

2. The Lactobacillus crispatus HGG35 according to claim 1, characterized in that The 16SrDNA sequence of the Lactobacillus crispatus HGG35 is shown in SEQ ID NO.

1.

3. A composition for preventing and / or treating premature birth, characterized in that: The composition comprises the Lactobacillus crispatus HGG35 according to claim 1 or 2.

4. The composition according to claim 3, characterized in that The concentration of Lactobacillus crispatus HGG35 in the composition is 10 7 ~10 9 CFU / mL.

5. Use of the Lactobacillus crispatus HGG35 according to claim 1 or 2 or the composition according to claim 3 or 4 in the preparation of a medicament for preventing and / or treating premature birth.

6. The use according to claim 5, characterized in that: The method of using the drug is vaginal implantation.

Images